[go: up one dir, main page]

EA200201213A1 - AROMATASE INHIBITORS AND MONOCLONAL ANTIBODIES AGAINST HER2 AS ANTI-TUMOR AGENTS - Google Patents

AROMATASE INHIBITORS AND MONOCLONAL ANTIBODIES AGAINST HER2 AS ANTI-TUMOR AGENTS

Info

Publication number
EA200201213A1
EA200201213A1 EA200201213A EA200201213A EA200201213A1 EA 200201213 A1 EA200201213 A1 EA 200201213A1 EA 200201213 A EA200201213 A EA 200201213A EA 200201213 A EA200201213 A EA 200201213A EA 200201213 A1 EA200201213 A1 EA 200201213A1
Authority
EA
Eurasian Patent Office
Prior art keywords
monoclonal antibodies
antibodies against
against her2
aromatase inhibitors
tumor agents
Prior art date
Application number
EA200201213A
Other languages
Russian (ru)
Other versions
EA005931B1 (en
Inventor
Джорджо Массимини
Дайнеш Пурандаре
Original Assignee
Фармация Италия С.П.А.
Фармация Энд Апджон Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Италия С.П.А., Фармация Энд Апджон Компани filed Critical Фармация Италия С.П.А.
Publication of EA200201213A1 publication Critical patent/EA200201213A1/en
Publication of EA005931B1 publication Critical patent/EA005931B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Способ лечения человека, страдающего гормонзависимым нарушением, характеризуемым сверхэкспрессией HER2, предусматривающий введение указанному человеку ингибитора ароматазы, например эксеместана, фадрозола, летрозола и анастрозола, и антитела против HER2, например трастузумаба, в количествах, эффективных для получения сверхаддитивного или синергичного, терапевтического эффекта.Международная заявка была опубликована вместе с отчетом о международном поиске.A method for treating a person suffering from a hormone-dependent disorder characterized by overexpression of HER2, which involves administering an aromatase inhibitor, for example, exemestane, fadrozole, letrozole and anastrozole, and an antibody against HER2, such as trastuzumab, to a specified person, in amounts effective for producing an extra additive or synergistic therapeutic effect. The application was published with the international search report.

EA200201213A 2000-05-15 2001-04-19 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents EA005931B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57135500A 2000-05-15 2000-05-15
PCT/EP2001/004468 WO2001087334A1 (en) 2000-05-15 2001-04-19 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents

Publications (2)

Publication Number Publication Date
EA200201213A1 true EA200201213A1 (en) 2003-04-24
EA005931B1 EA005931B1 (en) 2005-08-25

Family

ID=24283360

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200201213A EA005931B1 (en) 2000-05-15 2001-04-19 Aromatase inhibitors and monoclonal anti-her2 antibodies as antitumors agents

Country Status (20)

Country Link
EP (1) EP1282440A1 (en)
JP (1) JP2003533490A (en)
KR (1) KR20030014223A (en)
CN (1) CN1429118A (en)
AU (1) AU784617B2 (en)
BR (1) BR0110732A (en)
CA (1) CA2409652A1 (en)
CZ (1) CZ20023748A3 (en)
EA (1) EA005931B1 (en)
EE (1) EE200200622A (en)
HK (1) HK1054200A1 (en)
HU (1) HUP0301877A2 (en)
IL (1) IL152389A0 (en)
MX (1) MXPA02011194A (en)
NO (1) NO20025302D0 (en)
NZ (1) NZ523004A (en)
PL (1) PL360153A1 (en)
SK (1) SK16022002A3 (en)
WO (1) WO2001087334A1 (en)
ZA (1) ZA200209815B (en)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.
AUPQ105799A0 (en) 1999-06-18 1999-07-08 Victor Chang Cardiac Research Institute, The Cell growth inhibition
EP1282443B1 (en) 2000-05-19 2009-09-02 Genentech, Inc. Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy
ES2269682T3 (en) * 2001-01-26 2007-04-01 Pfizer Italia S.R.L. EXEMESTANE TO TREAT DISORDERS THAT DEPEND ON HORMONES.
GB2375958B (en) 2001-04-09 2005-03-02 George Margetts The use of steroids to lower the levels of cortisol
AU2003218600C1 (en) 2002-03-26 2009-12-17 Zensun (Shanghai) Science & Technology Co., Ltd. ERBB3 based methods and compositions for treating neoplasms
CN1678348A (en) * 2002-07-01 2005-10-05 萨文特医药公司 Compositions and methods for therapeutic treatment
FR2844455B1 (en) * 2002-09-13 2007-12-14 Lab Francais Du Fractionnement TREATMENT OF PATHOLOGIES EXCLUDING IMMUNE RESPONSE BY OPTIMIZED ANTIBODIES
CN101014365B (en) * 2004-07-16 2011-04-13 辉瑞产品公司 Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody
UA94899C2 (en) 2005-01-21 2011-06-25 Дженентек, Инк. Fixed dosing of her antibodies
EP1850874B1 (en) 2005-02-23 2013-10-16 Genentech, Inc. Extending time to disease progression or survival in ovarian cancer patients using pertuzumab
EP1945224B1 (en) 2005-10-19 2012-05-02 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
EP2132573B1 (en) 2007-03-02 2014-04-23 Genentech, Inc. Predicting response to a her dimerisation inhbitor based on low her3 expression
DK2171090T3 (en) 2007-06-08 2013-06-10 Genentech Inc Gene expression markers for tumor resistance to HER2 inhibitor therapy
US9551033B2 (en) 2007-06-08 2017-01-24 Genentech, Inc. Gene expression markers of tumor resistance to HER2 inhibitor treatment
BRPI0812682A2 (en) 2008-06-16 2010-06-22 Genentech Inc metastatic breast cancer treatment
ES2572728T3 (en) 2009-03-20 2016-06-02 F. Hoffmann-La Roche Ag Bispecific anti-HER antibodies
CA2761280A1 (en) 2009-05-29 2010-12-02 F. Hoffmann-La Roche Ag Modulators for her2 signaling in her2 expressing patients with gastric cancer
CN102892779B (en) 2010-02-18 2016-12-21 基因泰克公司 Neuregulin antagonist and the purposes in treatment cancer thereof
WO2011146568A1 (en) 2010-05-19 2011-11-24 Genentech, Inc. Predicting response to a her inhibitor
WO2012069466A1 (en) 2010-11-24 2012-05-31 Novartis Ag Multispecific molecules
JP5766296B2 (en) 2010-12-23 2015-08-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Polypeptide-polynucleotide complexes and their use in targeted delivery of effector components
CN102068429B (en) * 2010-12-28 2011-12-14 西南大学 Application of fadrozole in inducing transformation of differentiated ovary of tilapia mossambica into functional testis and induction method thereof
MX2014001766A (en) 2011-08-17 2014-05-01 Genentech Inc Neuregulin antibodies and uses thereof.
WO2013063229A1 (en) 2011-10-25 2013-05-02 The Regents Of The University Of Michigan Her2 targeting agent treatment in non-her2-amplified cancers having her2 expressing cancer stem cells
CN106987620A (en) 2011-11-30 2017-07-28 霍夫曼-拉罗奇有限公司 Erbb3 mutation in cancer
WO2013083810A1 (en) 2011-12-09 2013-06-13 F. Hoffmann-La Roche Ag Identification of non-responders to her2 inhibitors
JP2015514710A (en) 2012-03-27 2015-05-21 ジェネンテック， インコーポレイテッド Diagnosis and treatment of HER3 inhibitors
US20160038490A1 (en) * 2012-07-18 2016-02-11 Angion Biomedica Corp. Compositions and methods for treating dysproliferative diseases
WO2014083178A1 (en) 2012-11-30 2014-06-05 F. Hoffmann-La Roche Ag Identification of patients in need of pd-l1 inhibitor cotherapy
US10064874B2 (en) 2014-10-22 2018-09-04 Havah Therapeutics Pty Ltd. Methods of reducing mammographic breast density and/or breast cancer risk
AU2016343297A1 (en) 2015-10-22 2018-05-10 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
US20190151346A1 (en) 2016-05-10 2019-05-23 INSERM (Institute National de la Santé et de la Recherche Médicale) Combinations therapies for the treatment of cancer
CN107417791B (en) * 2017-08-17 2020-09-22 合肥瀚科迈博生物技术有限公司 Anti-human ErbB2 bispecific antibody, preparation method and application thereof
CN119970752A (en) 2019-06-03 2025-05-13 哈瓦赫治疗有限公司 Pharmaceutical formulations for delivery of androgens and aromatase inhibitors

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9811162B (en) * 1997-12-12 2000-06-07 Genentech Inc Treatment with anti-ERBB2 antibodies.

Also Published As

Publication number Publication date
SK16022002A3 (en) 2003-04-01
NO20025302L (en) 2002-11-05
HUP0301877A2 (en) 2003-09-29
CN1429118A (en) 2003-07-09
CZ20023748A3 (en) 2003-04-16
AU5630901A (en) 2001-11-26
PL360153A1 (en) 2004-09-06
ZA200209815B (en) 2003-12-03
WO2001087334A1 (en) 2001-11-22
EP1282440A1 (en) 2003-02-12
EA005931B1 (en) 2005-08-25
KR20030014223A (en) 2003-02-15
JP2003533490A (en) 2003-11-11
BR0110732A (en) 2003-02-04
AU784617B2 (en) 2006-05-18
HK1054200A1 (en) 2003-11-21
EE200200622A (en) 2004-06-15
NZ523004A (en) 2004-09-24
CA2409652A1 (en) 2001-11-22
MXPA02011194A (en) 2003-03-10
NO20025302D0 (en) 2002-11-05
IL152389A0 (en) 2003-05-29

Similar Documents

Publication Publication Date Title
EA200201213A1 (en) AROMATASE INHIBITORS AND MONOCLONAL ANTIBODIES AGAINST HER2 AS ANTI-TUMOR AGENTS
FI4175951T3 (en) Hpk1 inhibitors and uses thereof
EA202092933A1 (en) ANTIBODIES TO ENTPD2, TYPES OF COMBINATION THERAPY AND METHODS OF APPLICATION OF ANTIBODIES AND TYPES OF COMBINATION THERAPY
TW200509930A (en) Methods and compositions for treating rheumatoid arthritis
MX2024013016A (en) Methods for treating cancer with anti-pd-1 antibodies
DE69228556D1 (en) CDw52-SPECIFIC ANTIBODIES FOR TREATING MULTIPLE Sclerosis
RU2008137764A (en) METHODS FOR PREVENTING AND TREATING AMYLOID DISEASES
EA201001528A1 (en) Antibodies to sclerostina and methods of their use
ATE480566T1 (en) IMMUNOTHERAPEUTIC COMPOSITION AND METHOD FOR TREATING PROSTATE CANCER
ATE330631T1 (en) ANTIBODIES FRAGMENTS FOR THE LOCAL TREATMENT OF EYE DISEASES
DE602004028272D1 (en) USE OF ANTAGONIST ANTI-CD40 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF MULTIPLE MYELOMA
EA200401198A1 (en) ANTIBODIES AGAINST αvβ6
MA30654B1 (en) TUMOR THERAPY WITH ANTI-VEGF ANTIBODIES
TW200505481A (en) Compositions and methods for treating coagulation related disorders
NZ712762A (en) Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
EA200870141A1 (en) COMBINATION THERAPY USING ANTIBODIES TO EGFR AND HER2
MY208743A (en) Anti-ms4a4a antibodies and methods of use thereof
MX2022012182A (en) METHODS OF USE OF ANTI-TREM2 ANTIBODIES.
RU2010132178A (en) AGENTS REDUCING THE NUMBER OF B-CELLS, SUCH AS AN ANTIBODY AGAINST CD20 OR THEIR FRAGMENTS FOR TREATING A CHRONIC FATIGUE SYNDROME
EP1546205A4 (en) PROCESS FOR REGULATING CANCER
EA202192587A1 (en) ANTIBODIES TO CD73, ANTIBODIES TO PD-L1 AND CHEMOTHERAPY FOR TUMOR TREATMENT
EP1411962A4 (en) MONOCLONAL ANTIBODY TREATMENT OF PANCREATIC CANCER
EA200400930A1 (en) BLOCKING MONOCLONAL ANTIBODY TO VLA-1 OR ITS USE FOR THE TREATMENT OF INFLAMMATORY DISEASES
MX2022006728A (en) Methods and combinations for the treatment of cancer using immune checkpoint inhibitor antibodies.
ATE312622T1 (en) USE OF ANTI-HBP ANTIBODIES TO INHIBIT BRADYKININ RELEASE

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU